FORT WORTH, TX - Sanara MedTech Inc. (NASDAQ: SMTI), a company specializing in medical technology for surgical and chronic wound care, has entered into a $55 million term loan agreement with CRG Servicing LLC, an affiliate of healthcare investment fund CRG LP. The funding is aimed at supporting Sanara's growth plans for 2024 and 2025.
The company, which announced the financial deal today, received $15 million in gross proceeds at closing and has the option to draw up to an additional $40 million in two tranches before June 30, 2025. Sanara has used approximately $9.8 million from the initial proceeds to retire its existing debt, with the remaining funds earmarked for growth initiatives such as potential acquisitions, investments, working capital, and general corporate purposes.
Sanara is also in the process of negotiating a $10 million revolving line of credit with a commercial bank, which would be permitted under the CRG facility. CEO Zach Fleming expressed confidence in the partnership with CRG, emphasizing that the non-dilutive capital will support the company's strategic growth and potential acquisitions.
CRG Partner Luke Düster conveyed enthusiasm about the partnership, citing Sanara's proven track record and the company's portfolio of products that aim to improve patient outcomes and reduce healthcare costs.
Sanara MedTech's product offerings include a range of surgical and wound care products, such as CellerateRX® Surgical Activated Collagen®, and a suite of advanced biologic products. The company also provides telemedicine services for wound care and dermatology consultations.
This financial move is based on a press release statement and reflects Sanara MedTech's efforts to expand its business and product offerings in the healthcare market.
InvestingPro Insights
As Sanara MedTech Inc. (NASDAQ: SMTI) forges ahead with its growth strategy, bolstered by the recent $55 million term loan agreement, insights from InvestingPro reveal a nuanced picture of the company's financial health and market position. Sanara's impressive gross profit margin, which stands at 87.92% for the last twelve months as of Q4 2023, underscores the company's ability to efficiently manage the cost of goods sold relative to its sales—a promising sign for investors eyeing the company's profitability potential.
However, investors should note that the company is currently not profitable, with a negative P/E ratio of -61.35 and an adjusted P/E ratio for the last twelve months of -35.84. This reflects the challenges Sanara faces in turning its gross profits into net earnings. Additionally, the stock has experienced significant volatility, with a 1 Year Price Total Return of -34.04% as of the latest data, suggesting that while the company has potential, it may also carry a higher risk profile for investors.
With the stock's RSI indicating it is in oversold territory, there may be an opportunity for investors to consider entry points, especially if they are confident in Sanara's long-term growth plans. Nevertheless, Sanara's operations with a moderate level of debt and the absence of dividend payments to shareholders are factors that should be carefully weighed.
For those looking to delve deeper into Sanara MedTech's prospects, additional InvestingPro Tips can provide further guidance. There are a total of 8 InvestingPro Tips available, which can be accessed through Investing Pro. For readers seeking to take advantage of these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.